Antonio Cano

A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate

P. Neven, P. Benedetti‐Panici, T. Nickelsen, 2003, BJOG : an international journal of obstetrics and gynaecology.

Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.

Z. Benítez, T. Simoncini, J. Calaf, 2022, Maturitas.

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

R. Thurston, N. Santoro, F. Ottery, 2023, The Lancet.

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause

N. Santoro, F. Ottery, G. Neal-Perry, 2023, Obstetrics and gynecology.

Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts’ perspective

N. Panay, M. Gambacciani, S. Rozenberg, 2023, Expert review of clinical pharmacology.

BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

T. Simoncini, S. Davis, N. Panay, 2021, Post reproductive health.

A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate

P. Neven, P. Benedetti‐Panici, T. Nickelsen, 2003, BJOG : an international journal of obstetrics and gynaecology.

Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre.

A. Cano, Antonio Cano, 1994, Maturitas.

Evaluation of the risk factors of asymptomatic vertebral fractures in postmenopausal women with osteopenia at the femoral neck.

Antonio Cano, F. Baró, V. Inaraja, 2016, Maturitas.